ArticleRevista da Associacao Medica Brasileira (1992)2025
Could carbonic anhydrase IX predict fetal growth restriction in early onset preeclampsia?
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePlacental insufficiency, which plays a crucial role in both preeclampsia and fetal growth restriction, can cause oxidative stress and high reactive oxygen species production that could lead to hypoxia. Carbonic anhydrase IX is induced by hypoxia-inducible factor-1α, an important transcriptional regulator of genes involved in response to hypoxia. Considering this, we aimed to determine carbonic anhydrase IX levels in early preeclampsia with and without fetal growth restriction, and also to evaluate the predictive role of carbonic anhydrase IX for the development of fetal growth restriction in early onset preeclampsia.
methodsThis prospective study included a total of 180 participants, who were divided into two groups-early onset preeclampsia (n=90) and control (n=90). Then, preeclamptic patients were followed and subgrouped as preeclampsia with fetal growth restriction (n=35) and without fetal growth restriction (n=55). Sociodemographic and obstetric characteristics and laboratory features including carbonic anhydrase IX were compared between groups.
resultsMedian carbonic anhydrase IX was higher in preeclampsia than controls [2.07 (0.78-5.48) vs. 1.32 (0.63-2.12), p<0.001]. Moreover, median carbonic anhydrase IX was higher in the preeclampsia with fetal growth restriction group as compared to the preeclampsia without fetal growth restriction group [2.76 (0.78-5.48) vs. 1.77 (0.89-5.14), p=0.018]. The carbonic anhydrase IX >1.83 pg/mL predicted fetal growth restriction with 77.14% sensitivity and 52.73% specificity (p=0.015, AUC=0.649) in the early onset preeclampsia.
conclusionCarbonic anhydrase IX could reflect the insufficiency of the placenta in early onset preeclampsia and fetal growth restriction, and it could be used in early onset preeclampsia patients for the prediction of fetal growth restriction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.